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Abstract
Introduction: Vancomycin-resistant Enterococcus (VRE) is one of the most important causative organisms 
of nosocomial infections. Once VRE outbreaks occur in hospitals, enormous efforts must be made to control them, 
especially in wards housing neutropenic or transplant patients. The purpose of this meta-analysis was to investigate the 
efficacy and adverse event profile of linezolid versus that of Quinupristin-Dalfopristin for the treatment of VRE infections.
Methodology: Literature searches of PubMed, MEDLINE, and EMBASE databases were performed on April 5, 
2017 using combined text words with the following MeSH/EMTREE terms: “linezolid” and “Quinupristin-Dalfopristin” and 
“Enterococcus” and “human.” The odds ratios (ORs) with 95% confidence intervals (CIs) for individual studies were 
calculated and pooled separately. The pooled estimates were combined using the inverse variance weighting scheme 
and random effect method.
Results: A systematic search identified 674 articles, and five involving 333 patients were included in the final analysis. 
One study was a prospective randomized controlled trial, and four were retrospective studies. The mortality rate in the 
groups of patients treated with linezolid was significantly lower than that in patients treated with Quinupristin-Dalfopristin 
(OR: 0.47; 95% CI: 0.23 to 0.97; heterogeneity P=0.13, Z=2.05, P=0.04; I2=44%; Begg’s test: P=0.33; Egger’s test: P=0.78). 
The clinical and microbiological responses indicated no significant differences between the linezolid and Quinupristin-
Dalfopristin groups (58% and 43%, respectively, P=0.6; OR: 1.51; 95% CI: 0.75 to 3.04; heterogeneity P=0.32; Z=1.15, 
P=0.25; I2=0%). The adverse event proiles differed between the Linezolid and quinupristin-dalfopristin groups.
Conclusion: Our results suggest a significantly lower mortality rate in patients treated with linezolid than in those 
treated with Quinupristin-Dalfopristin for VRE infections; however, this was limited by a variety of factors (mostly 
retrospective).
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Introduction
Vancomycin-resistant Enterococcus (VRE) is one of the most 
important causative organisms of nosocomial infections. VRE was first 
reported in the UK and France in 1988 [1,2]. Since then, VRE has spread 
in medical settings worldwide including the US and European countries 
[3-5]. Linezolid, Quinupristin-Dalfopristin, and daptomycin are anti-
infective agent approved in the US in 2000. It can be administered 
either intravenously or orally; however, its use poses the potential 
risk of bone marrow toxicity and neuropathy. Serotonergic drug 
interactions are another drawback of linezolid therapy. Birmingham et 
al. [6] showed that the evaluable clinical and microbiological response 
rates of linezolid in the treatment of VRE infections were 73% and 84%, 
respectively.
Quinupristin-Dalfopristin is a streptogramin antibiotic used for the 
treatment of VREF that was approved in the US and the UK in 1999. It 
should be used with caution owing to the risk of side effects (arthralgias, 
myalgias, and infusion-related side effects), potential drug-drug 
interactions, and low efficacy against E. faecalis [7]. Linden et al. [8] 
showed that the clinical response rate of Quinupristin-Dalfopristin in 
the treatment of VREF infections was 68.8% in an evaluable subset. Both 
linezolid and Quinupristin-Dalfopristin are bacteriostatic against VRE 
[9]. There are currently few studies comparing the outcomes of patients 
treated with linezolid versus those of Quinupristin-Dalfopristin for 
VRE infections. Thus, more studies are needed to evaluate the efficacy 
outcomes of linezolid and Quinupristin-Dalfopristin in the treatment 
of VRE infections.
Daptomycin is a cyclic lipopeptide antibiotic with activity against 
VRE [9]. Two recent meta-analyses showed lower mortality for VRE 
bacteremia treatment with linezolid than with daptomycin, but these 
studies were limited by a variety of factors [10-12].
The purpose of this meta-analysis was to compare the efficacy 
and adverse event profiles of linezolid versus those of Quinupristin-
Dalfopristin in the treatment of VRE infections.
Materials and Methods
Literature search
This meta-analysis was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
infective agents used to treat vancomycin-resistant Enterococcus 
faecium (VREF) infections. Linezolid was the first oxazolidinone anti-
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statement [13]. Literature searches of the PubMed MEDLINE database 
(from January 1, 1966) and EMBASE (from January 1, 1974) were 
performed on April 5, 2017, using combined text words with the 
following MeSH/EMTREE terms: “linezolid” and “Quinupristin-
Dalfopristin” and “Enterococcus” and “human.” The references of the 
identified studies and reviews were also scanned to identify additional 
relevant studies, and no language restriction was imposed.
Study selection and data extraction
Study selection and data extraction were conducted independently 
by two investigators (TW and RU), and disagreements or uncertainties 
were resolved by discussion among all the authors to reach a consensus. 
Studies were included in this meta-analysis if they were published 
clinical trials or observational studies that simultaneously reported 
the outcome (mortality) of the treatment of VRE infections with 
linezolid and Quinupristin-Dalfopristin. Articles were excluded 
from the analysis if they were reviews or letters, and all prospective 
and retrospective studies were included. Only the most recent study 
was included when duplicated studies on the same population were 
identified. The following information was extracted from each study: 
author, publication year, country, study duration, study design, study 
size, mean age, type of infection, acute physiology and chronic health 
evaluation (APACHE) II score, duration of treatment, mortality, 
clinical response, and microbiological response. The primary outcome 
assessed in this meta-analysis was overall mortality. The clinical and 
microbiological responses were also evaluated. Attempts were made 
to contact the corresponding authors of studies with insufficient data 
when necessary.
Statistical analysis
The odds ratios (ORs) with 95% confidence intervals (CIs) were 
calculated and pooled separately for individual studies. The pooled 
estimates were combined using the inverse variance weighting 
scheme and random effect method [14]. The heterogeneity among 
the studies was estimated using the I2 and Cochran’s Q statistics [14]. 
The publication bias was investigated using funnel plots and further 
assessed using Begg’s rank correlation and Egger’s linear regression 
tests [15,16]. All statistical analyses were performed using the Review 
Manager Version 5.3 (Revman, The Cochrane Collaboration, Oxford, 
UK).
Results
Search results
The systematic search identified 674 articles, which included 20 
duplicates. After title and abstract screening, 175 full-text articles were 
reviewed, and 170 were subsequently excluded. During the process of 
abstracting data from the identified articles and reviews, no additional 
references were identified, and five articles were subsequently included 
in the final analysis (Figure 1).
Study characteristics
The characteristics of the eligible studies are shown in Table 1. 
One study was a prospective randomized controlled trial, and four 
were retrospective studies [17-21]. All the studies were single-center 
experiences published between 2004 and 2010 in the US and Korea, 
and 333 patients were identified. Sample sizes of 208 and 125 patients 
were selected for the linezolid and Quinupristin-Dalfopristin groups, 
respectively. The attempts to contact the corresponding authors of the 
four studies with insufficient data yielded no additional data [18-21].
Meta-analyses
The five included studies reported the mortality of 333 patients 
treated with linezolid (n=208) and Quinupristin-Dalfopristin (n=125) 
[17-21]. The mortality rate was significantly lower in patients treated 
with linezolid than it was in those treated with Quinupristin-Dalfopristin 
(OR: 0.47; 95% CI, 0.23 to 0.97; heterogeneity P=0.13; Z=2.05, P=0.04; 
I2=44%; Begg’s test: P=0.33; Egger’s test: P=0.78 (Figure 2a). Clinical 
responses were reported in only one study and, therefore, we could 
not perform a meta-analysis. The clinical response was comparable 
Reports identified through PubMed MEDLINE and 
EMBASE searching (n=674)
Records screened (n=654)
Full-text articles assessed for eligibility (n=175)
Studies included in the meta-analysis (n=5)
Excluded by screening title and abstract (n=479)
Experimental studies (n=1)
Observational studies (n=17)
Case reports (n=73)
Laboratory/Non-human/Ecological studies (n=137)
Review articles (n=221)
Commentaries/Letters/Other (n=30)
Duplicates removed (n=20)
Full-text articles excluded (n=170)
Experimental studies (n=0)
Observational studies (n=20)
Case reports (n=7)
Laboratory/Non-human/Ecological studies (n=8)
Review articles (n=127)
Commentaries/Letters/Other (n=8)
 Figure 1: Flow diagram for selection of articles for inclusion in meta-analysis.
Volume 5 • Issue 2 • 1000318J Infect Dis Ther, an open access journalISSN: 2332-0877
Citation: Watanabe T, Uchida R, Handa S, Shindo M, Kato I, et al. (2017) Comparative Efficacy and Safety of Linezolid and Quinupristin-Dalfopristin in 
the Treatment of Vancomycin-Resistant Enterococcus Infections: A Meta-Analysis. J Infect Dis Ther 5: 318. doi:10.4172/2332-0877.1000318
Page 3 of 5
between the linezolid and Quinupristin-Dalfopristin groups (58% and 
43%, respectively, P=0.6) [17]. Two studies reported microbiological 
responses, and the results indicated no significant difference between 
the linezolid and Quinupristin-Dalfopristin groups (OR: 1.51; 95% CI, 
0.75 to 3.04; heterogeneity P=0.32; Z=1.15, P=0.25; I2=0%, (Figure 2b) 
[17,21]. Begg’s and Egger’s tests were not carried out for microbiological 
response because only two studies were included.
Discussion
The results of this meta-analysis suggest that the mortality rate 
of the groups of patients treated with linezolid was significantly 
lower than that of the Quinupristin-Dalfopristin-treated groups. The 
Quinupristin-Dalfopristin group tended to show a lower rate of clinical 
and microbiological responses than the linezolid group did, but the 
differences were not significant. More studies would be needed to make 
reliable quantitative statements about the differences in the clinical and 
microbiological responses between the linezolid and Quinupristin-
Dalfopristin groups.
Linezolid treatment has been associated with reversible 
myelosuppression as well as thrombocytopenia and a slight increase 
Author and year Country Study duration Study design
Study size 
(no. of patients) Mean age (SD)
Type of infection 
(no. of patients)
APACHE II, 
mean (SD)
Duration of treatment, 
mean days (SD)
LZD Q-D LZD Q-D LZD Q-D LZD Q-D
Raad et al., 2004 
[17] US 1998–2001
Prospective, 
randomized study 19 21
54.2 
(16.0)
53.4 
(14.4)
Bacteremia (37), 
surgical wound 
infection (2), and 
upper urinary tract 
infection (1)
13.8 
(4.1)
14.3 
(3.8) 14.7 (9.6) 10.9 (4.6)
Gearhart M et al., 
2005 [18] US 1995–2002
Retrospective 
study 6 8 NA NA
Sites of VRE cultures 
in the 
infected patients were 
blood, peritoneal fluid, 
bile, urine culture, 
feces, others (detailed 
data was not shown).
NA NA NA NA
Erlandson et al., 
2008 [19] US 1993–2005
Retrospective 
study 71 20
34.0 
(29.0)
44.7 
(19.2) Bacteremia (91)
17.0 
(6.6) 21 (6.9)
14 (range, 
3–70)
12 (range, 
2–42)
Han et al., 2009 [20] Korea 1998–2007 Retrospective study 51 24 58 (44–66) 
a Bacteremia (75) 14 (12–20) a 14 (7–20) a
Chong et al., 2010 
[21] Korea 2003–2007
Retrospective 
study 61 52 50 (17) 51 (16) Bacteremia (113) 18 (7) 16 (6) 16 (9) 12 (8)
APACHE, Acute Physiology and Chronic Health Evaluation; LZD: Linezolid; NA: Not Applicable; Q-D: Quinupristin-Dalfopristin; SD: Standard Deviation; VRE: Vancomycin 
Resistant Enterococcus
a interquartile range.
Table 1: Characteristics of eligible studies.
a)
Forest plot of comparison: Linezolid versus quinupristin-dalfopristin; Outcome: mortality. (Begg’s test, P = 0.33; Egger’s test, P = 0.78) 
b)
Forest plot of comparison: Linezolid versus quinupristin-dalfopristin; Outcome: microbiological response. 
Figure 2: Forest plot showing effect of linezolid versus quinupristin-dalfopristin in the treatment of vancomycin-resistant Enterococcus infections; a: Forest plot of 
comparison: Linezolid versus quinupristin-dalfopristin; Outcome: mortality. (Begg’s test: P=0.33; Egger’s test: P=0.78); b: Forest plot of comparison: Linezolid versus 
quinupristin-dalfopristin; Outcome: microbiological response.
Volume 5 • Issue 2 • 1000318J Infect Dis Ther, an open access journalISSN: 2332-0877
Citation: Watanabe T, Uchida R, Handa S, Shindo M, Kato I, et al. (2017) Comparative Efficacy and Safety of Linezolid and Quinupristin-Dalfopristin in 
the Treatment of Vancomycin-Resistant Enterococcus Infections: A Meta-Analysis. J Infect Dis Ther 5: 318. doi:10.4172/2332-0877.1000318
Page 4 of 5
in the risk of developing anemia [22]. Conversely, the most common 
systemic adverse events related to treatment with Quinupristin-
Dalfopristin are arthralgias and myalgias [23]. The adverse event profiles 
for the eligible studies in our report are shown in Table 2. Raad et al. 
[17] showed that the rate of myalgias/arthralgias was 33% (7/21) in the 
Quinupristin-Dalfopristin study group (P<0.01); however, in all seven 
cases, myalgias/arthralgias resolved when the drug was discontinued. 
Chong et al. [21] reported that antibiotic-induced thrombocytopenia 
was observed only in three patients in the linezolid group (5%), but 
their platelet counts recovered after linezolid therapy was discontinued. 
These findings suggest differences in adverse event profiles of linezolid 
and Quinupristin-Dalfopristin groups.
The increasing incidence of antibiotic-resistant nosocomial 
pathogens including linezolid- and Quinupristin-Dalfopristin-resistant 
Enterococcus is a global problem [7,24,25]. Univariable analysis of 
a retrospective study revealed the risk factors for reduced linezolid 
susceptibility. These factors included allogeneic hematopoietic stem 
cell or solid organ transplants or both, as well as the administration 
of immunosuppressive medications including corticosteroids, non-
corticosteroids, and linezolid within 1 year prior to the infection [26]. 
The intensive use of linezolid was subsequently associated with the 
development of decreased VREF susceptibility to this antibiotic [27]. 
Therefore, caution should be exercised in empiric therapy or therapy in 
patients with reduced susceptibility. Two recent meta-analyses showed 
that linezolid treatment of VRE bacteremia was associated with a lower 
mortality than daptomycin treatment was [10,11]. However, Anastasiou 
et al. [28] reported that resistance to linezolid and Quinupristin-
Dalfopristin appeared to be independent of daptomycin susceptibility, 
and no significant cross-resistance was noted. Therefore, daptomycin 
has the potential to be a useful therapeutic agent for treating VRE 
infections.
Our study had several limitations that are worth mentioning. The 
majority of the included studies had some methodological limitations 
(mostly retrospective), and many lacked detailed case information. 
Furthermore, the attempts to contact the corresponding authors of 
studies with insufficient data were unproductive, as no additional data 
were obtained. There was also evidence of heterogeneity and publication 
bias. The differences in baseline risks between the groups in the included 
studies likely played a role in the bias since the linezolid-treated groups 
appeared to include fewer transplant recipients, APACHE II scores, 
and renal dysfunction than the Quinupristin-Dalfopristin-treated 
groups did. However, each of these studies targeted linezolid versus 
Quinupristin-dalfopristin in the treatment of VRE bacteremia and, 
therefore, we believe that our study contributes valuable information to 
the current efforts and strategies to control VRE infections.
Conclusion
Enterococcus is one of the most important causative organisms 
of nosocomial infection, and VRE outbreaks in hospitals need to 
be controlled aggressively and promptly to prevent the associated 
mortalities. Our results suggest that the mortality rate was significantly 
lower in the groups of patients treated with linezolid than in those treated 
with Quinupristin-Dalfopristin; however, these findings are limited by 
a variety of factors. Additional larger, randomized, controlled trials are 
needed to evaluate the efficacy and safety of linezolid and Quinupristin-
Dalfopristin in the treatment of VRE infections. In addition, the 
antibiotic choice in the treatment of VRE for individual patients should 
be considered based on local availability, antibiotic resistance patterns, 
the risk of adverse events, and cost, and our findings would be useful in 
making informed decisions.
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